<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90660">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827553</url>
  </required_header>
  <id_info>
    <org_study_id>2009-014476-21</org_study_id>
    <nct_id>NCT01827553</nct_id>
  </id_info>
  <brief_title>Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy</brief_title>
  <acronym>CONKO-007</acronym>
  <official_title>Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial examines the effectiveness of chemoradiotherapy compared to
      chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of
      FOLFIRINOX in patients with locally advanced, non resectable and non-metastatic pancreatic
      cancer. Chemotherapeutic agent in chemoradiotherapy is gemcitabine administered in 5 cycles,
      the agent and its administration for sole chemotherapy is determined by induction
      chemotherapy. Operability of tumor is evaluated four weeks after end of treatment. Patients
      will be followed for the duration of therapy and for 5 years after the last study treatment.
      Overall survival at the end of follow up is defined as primary endpoint. Secondary endpoints
      are tumor-free survival, rate of local recurrence or local progression, rate of distant
      metastasis, acute and late toxicity of the chemoradiotherapy, quality of life, rate of
      remission, rate of curative resections (R0) after chemotherapy and chemoradiotherapy. It is
      planned to include a total number of 830 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-free survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of local recurrence or local progression</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastasis</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity of the chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of remission</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curative resections (R0) after chemotherapy and chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">830</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy with gemcitabine or FOLFIRINOX</intervention_name>
    <description>According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy, 28 x 1.8 Gy</intervention_name>
    <description>Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy, gemcitabine</intervention_name>
    <description>5 cycles of 300 mg/m^2/d gemcitabine infusions</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <other_name>all brands of gemcitabine are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</intervention_name>
    <description>Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 2 cycles a 3 administrations of 300 mg/m^2/d gemcitabine infusions FOLFIRINOX: 4 cycles</description>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  histologically confirmed adenocarcinoma of the pancreas

          -  no evidence of distant metastasis based on computed tomography of the thorax and
             abdomen

          -  non resectable pancreatic cancer

          -  no evidence of peritoneal carcinosis

          -  ECOG-performance status ≤ 2

          -  signed study-specific consent form prior to therapy

        Exclusion Criteria:

          -  fertile patients who refuse effective contraception during study treatment

          -  synchron second malignant neoplasm except basal cell carcinoma of the skin and
             carcinoma in situ of the cervix after curative therapy

          -  the Inclusion of patients with prior or concurrent malignancy (≤ 5 years prior to
             enrolment in study) must be discussed

          -  chronic inflammatory disease of the intestine

          -  known allergic reactions on study medication

          -  on-treatment participation on other trials

          -  insufficient liver function: Bilirubin &gt; 2,0 mg/dl; SGOT, SGPT, alkaline phosphatase,
             gGT more than 3 times upper limit of normal (after Stent implantation in case of
             obstructive jaundice); cirrhosis of the liver Child B and C

          -  insufficient bone marrow function: WBC &lt; 3,0 x 10^9/l, Platelets &gt; 100 x 10^9/l

          -  serum creatinine &gt; 1,5 mg/dl, creatinin clearance &lt; 60ml/min (or comparable test)

          -  preexisting uncontrolled cardiac disease, signs of cardiac failure, or rhythm
             disturbances requiring therapy, myocardial infarction within the past 6 months,
             unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA)
             class III or IV heart disease

          -  neurological and/or psychiatric diseases: stroke, dementia, epilepsy, psychosis

          -  active intractable or uncontrollable infection, HIV-infection

          -  prior radiotherapy or chemotherapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Fietkau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Semrau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aachen Universitätsklinikum</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Peter Neumann, MD</last_name>
      <email>chirurgie@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Karsten Junge, MD</last_name>
      <email>kjunge@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulf Peter Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karsten Junge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augsburg Klinikum, III. Medizinische Klinik</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Messmann, MD</last_name>
      <email>helmut.messmann@klinikum-augsburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Probst, MD</last_name>
      <email>andreas.probst@klinikum-augsburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Messmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Probst, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayreuth, Klinikum</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Keilholz, MD</last_name>
      <email>ludwig.keilholz@klinikum-bayreuth.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Kiani, MD</last_name>
      <email>alexander.kiani@klinikum-bayreuth.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ludwig Keilholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Kiani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin, Charité Universitätsmedizin, Hämatologie/Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, MD</last_name>
      <email>marianne.sinn@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Uwe Pelzer, MD</last_name>
      <email>uwe.pelzer@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marianne Sinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uwe Pelzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin-Lichtenberg, Sana-Klinikum, Hämatologie/Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yüksel Atas, MD</last_name>
      <email>y.atas@sana-kl.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Schmöcker, MD</last_name>
      <email>c.schmoecker@sana-kl.de</email>
    </contact_backup>
    <investigator>
      <last_name>Yüksel Atas</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Schmöcker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bochum, Augusta-Kranken-Anstalt, Hämatologie/Onkologie</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Behringer, MD</last_name>
      <email>behringer@augusta-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Brandt</last_name>
      <email>brandt@augusta-bochum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Behringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Brandt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bochum, St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar Uhl, MD</last_name>
      <email>w.uhl@klinikum-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter R Ritter, MD</last_name>
      <email>peter.r.ritter@ruhr-uni-bochum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Waldemar Uhl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter R Ritter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brandenburg Städtisches Klinikum</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Mantke, MD</last_name>
      <email>mantke@klinikum-brandenburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Markus Deckert, Deckert</last_name>
      <email>deckert@klinikum-brandenburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>René Mantke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Markus Deckert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coburg Klinikum</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Grabenbauer, MD</last_name>
      <email>strahlentherapie@diacura.de</email>
    </contact>
    <contact_backup>
      <last_name>Christof Lamberti, MD</last_name>
      <email>christof.lamberti@klinikum-coburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerhard Grabenbauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Lamberti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dresden Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Jacobasch, MD</last_name>
      <email>jacobasch@onkologie-dresden.net</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Wolf, MD</last_name>
      <email>wolf@onkologie-dresden.net</email>
    </contact_backup>
    <investigator>
      <last_name>Lutz Jacobasch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlangen Universitätsklinikum</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Fietkau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Semrau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rainer Fietkau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Semrau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Esslingen Klinikum, Hämatologie/Onkologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frankfurt/Main Universitätsklinikum</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus M Rödel, MD</last_name>
      <email>claus.roedel@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Detlef Imhoff, MD</last_name>
      <email>strahlentherapie@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claus M Rödel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Detlef Imhoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freiburg Universitätsklinikum</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Wittel, MD</last_name>
      <email>uwe.wittel@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich T Hopt, MD</last_name>
      <email>ulrich.hopt@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Wittel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich T Hopt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Friedrichshafen Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Oettle, MD</last_name>
      <email>helmut.oettle@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Mayer, MD</last_name>
      <email>frank.mayer@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Oettle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Oberland, Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Lambertz, MD</last_name>
      <email>helmut.lambertz@klinikum-gap.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Weber</last_name>
      <email>daniel.weber@klinikum-gap.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Lambertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Weber</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Halle St. Elisabeth und St. Barbara Krankenhaus</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Opitz, MD</last_name>
      <email>b.opitz@krankenhaus-halle-saale.de</email>
    </contact>
    <contact_backup>
      <last_name>Judith Böhme, MD</last_name>
      <email>j.boehme@krankenhaus-halle-saale.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bernhard Opitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Böhme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heilbronn SLK-Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, MD</last_name>
      <email>uwe.martens@slk-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Lindauer, MD</last_name>
      <email>markus.lindauer@slk-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Martens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Lindauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homburg Universitätsklinikum</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Lammert, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Simone Zimmermann, MD</last_name>
      <email>simone.zimmmermann@uks.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Lammert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Zimmermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jena Universitätsklinikum</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Lindig, MD</last_name>
      <email>udo.lindig@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Ekkehard Eigendorff, MD</last_name>
      <email>ekkehard.eigendorff@med.uni-jena.de</email>
    </contact_backup>
    <investigator>
      <last_name>Udo Lindig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekkehard Eigendorff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köln Universitätsklinikum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Waldschmidt, MD</last_name>
      <email>dirk.waldschmidt@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Arnulf H Hölscher, MD</last_name>
      <email>Arnulf.Hoelscher@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Waldschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnulf H Hölscher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köln Kliniken</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Niehoff, MD</last_name>
      <email>niehoffp@kliniken-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Birgitta Bungart, MD</last_name>
      <email>bungart@kliniken-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Niehoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Birgitta Bungart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg Klinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Ridwelski, MD</last_name>
      <email>karsten.ridwelski@klinikum-magdeburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Kahl, MD</last_name>
      <email>christoph.kahl@klinikum-magdeburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Karsten Ridwelski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Kahl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg Universitätsklinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Stübs, MD</last_name>
      <email>patrick.stuebs@med.ovgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Garlipp, MD</last_name>
      <email>benjamin.garlipp@med.ovgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Stübs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Garlipp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mainz Universitätsmedizin</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Schmidberger, MD</last_name>
      <email>heinz.schmidberger@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Silla Hey-Koch, MD</last_name>
      <email>silla.hey-koch@unimedizin-mainz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heinz Schmidberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silla Hey-Koch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marburg Universitätsklinikum</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Michl, MD</last_name>
      <email>michlp@med.uni-marburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Sebastian Krug, MD</last_name>
      <email>krugs@med.uni-marburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Michl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Krug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>München Großhadern LMU</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, MD</last_name>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Böck, MD</last_name>
      <email>sekrmed3@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Böck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Münster Universitätsklinikum</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Anthoni, MD</last_name>
      <email>christoph.anthoni@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Palmes, MD</last_name>
      <email>palmes@uni-muenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Anthoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Palmes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ostfildern Paracelsus Krankenhaus Ruit</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Geiger, MD</last_name>
      <email>m.geiger@kk-es.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Morell, MD</last_name>
      <email>n.morell@kk-es.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Geiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Morell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regensburg Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Moosmann, MD</last_name>
      <email>nicolas.moosmann@barmherzige-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Schlenska-Lange, MD</last_name>
      <email>anke.schlenska-lange@barmherzige-regensburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Moosmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anke Schlenska-Lange, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stuttgart Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Denzlinger, MD</last_name>
      <email>inn3@vinzenz.de</email>
    </contact>
    <contact_backup>
      <last_name>Mona Rohm</last_name>
      <email>monarohm@vinzenz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Denzlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona Rohm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trier Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Kirchen, MD</last_name>
      <email>h.kirchen@bk-trier.de</email>
    </contact>
    <contact_backup>
      <last_name>Monika Lankeshofer-Loch</last_name>
      <email>m.lankeshofer-loch@bk-trier.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heinz Kirchen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Lankeshofer-Loch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tübingen Universitätsklinikum</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bitzer, MD</last_name>
      <email>michael.bitzer@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ruben Plentz, MD</last_name>
      <email>Ruben.plentz@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bitzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruben Plentz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Würzburg CCC Mainfranken</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Guckenberger, MD</last_name>
      <email>guckenberg_m@klinik.uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Volker Kunzmann, MD</last_name>
      <email>kunzmann_v@klinik.uni-wuerzburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Guckenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Kunzmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>April 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>gemcitabine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
